Award details

Further development of an African swine fever virus live attenuated vaccine

Reference	BB/L004267/1
Principal Investigator / Supervisor	Dr Linda Dixon
Co-Investigators / Co-Supervisors	Dr Christopher Netherton, Dr Geraldine Taylor
Institution	The Pirbright Institute
Department	Vector-borne Viral Diseases
Funding type	Research
Value (£)	550,630
Status	Completed
Type	Research Grant
Start date	17/02/2014
End date	16/08/2017
Duration	42 months

Abstract

unavailable

Summary

African swine fever virus (ASFV) causes a severe disease of domestic pigs that can result in up to 100% mortality and has severe socio-economic impacts. ASFV is endemic in most sub-Saharan African countries and Sardinia. Since introduction of ASF in 2007 to Georgia, the disease has rapidly spread through the Russian Federation and the risk of further spread has increased. The lack of a vaccine limits options for disease control. Attenuated ASFV strain OURT88/3 induces good levels of protection in pigs against lethal challenge with virulent virus. Commercial development of this strain as a vaccine has been hampered by the lack of a suitable cell line to propagate the virus. We have now identified a pig macrophage cell line can be infected by OURT88/3 strain and the virus grown in these cells can still induce protection in pigs. We will investigate the use of this cell line for ASFV vaccine strain production and diagnosis. We will also identify partners for commercial development

Committee	Not funded via Committee
Research Topics	Animal Health, Immunology, Microbiology
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund Super (SuperFOF) [2012-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search